STALICLA to In-License SFX-01 From Evgen for Neurodevelopment Disorder Indications, Including Autism Spectrum Disorder

The Life Sciences team advised STALICLA on its worldwide in-licensing of SFX-01, a patented composition of synthetic sulforaphane and alpha-cyclodextrin, from Evgen Pharma in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism Spectrum Disorder.

STALICLA is a precision molecular neuroscience clinical stage biotech company, advancing the first precision medicine platform for patients with neurodevelopmental disorders, and neuropsychiatric disorders.

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases.

The Goodwin team was led by Tim Worden, Kristopher Brown.

For more details, read the press release.